Comparison of the pharmacokinetics, safety and tolerability of daptomycin in healthy adult volunteers following intravenous administration by 30 min infusion or 2 min injection
Open Access
- 22 April 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 64 (1) , 151-158
Abstract
Two randomized Phase I studies in separate populations of healthy adult volunteers investigated the pharmacokinetics, safety and tolerability of daptomycin (Cubicin®; Novartis Pharma AG, Basel, Switzerland) administered as a 2 min intravenous (iv) injection, relative to the currently licensed 30 min iv infusion. Study 1 was an open-label, single-dose, two-period, crossover study in which each subject received 6 mg/kg daptomycin administered as a 30 min iv infusion (n = 15) and as a 2 min iv injection (n = 16). In Study 2, a single-blind, multiple-dose, parallel-group study, subjects received a once-daily 2 min iv injection of 6 mg/kg daptomycin (n = 12), 4 mg/kg daptomycin (n = 8) or placebo (n = 4) for 7 days. Single-dose pharmacokinetics were assessed at various timepoints up to 36 and 24 h post-dose in Study 1 and Study 2, respectively, and multiple-dose pharmacokinetics were assessed in Study 2 at day 7 for 48 h post-dose. In Study 1, pharmacokinetic comparability between the two administration regimens was demonstrated by meeting the bioequivalence criteria for the exposure parameters, AUC0–t, AUC0–∞ and Cmax. In Study 2, time-invariant pharmacokinetic properties as well as dose-proportional pharmacokinetics were demonstrated for the daptomycin 2 min iv injection regimen. In both studies, daptomycin was well tolerated and the majority of treatment-emergent adverse events were of mild intensity and considered to be unrelated to daptomycin. The similar pharmacokinetic and safety profiles of the two administration regimens suggest that the 2 min iv injection may be a convenient treatment option for both patients and healthcare professionals.Keywords
This publication has 20 references indexed in Scilit:
- Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers2008
- Inhibitory Activities of 11 Antimicrobial Agents and Bactericidal Activities of Vancomycin and Daptomycin against Invasive Methicillin-ResistantStaphylococcus aureusIsolates Obtained from 1999 through 2006Antimicrobial Agents and Chemotherapy, 2008
- Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005)BMC Infectious Diseases, 2007
- Pharmacokinetics and Tolerability of Daptomycin at Doses up to 12 Milligrams per Kilogram of Body Weight Once Daily in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2006
- Antimicrobial susceptibility of Gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002–2004)Clinical Microbiology and Infection, 2006
- Antimicrobial activity of daptomycin tested against clinical strains of indicated species isolated in North American medical centers (2003)Diagnostic Microbiology and Infectious Disease, 2005
- DaptomycinIn VitroActivity Tested Against Gram-Positive Strains Collected from European and Latin American Medical Centers in 2003Journal of Chemotherapy, 2005
- Antimicrobial activity of daptomycin against multidrug-resistant gram-positive strains collected worldwideDiagnostic Microbiology and Infectious Disease, 2004
- Population Pharmacokinetics of DaptomycinAntimicrobial Agents and Chemotherapy, 2004
- Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2003